Item 1.01. Entry into a Material Definitive Agreement.

On July 7, 2021, ARCA biopharma, Inc. ("ARCA") announced it had entered into a patent assignment agreement (the "Agreement") with the University Medical Center of Johannes Gutenberg University Mainz, Germany.

Under the terms of the Agreement, ARCA received exclusive world-wide patent rights relating to the use of rNAPc2 as a potential treatment for COVID-19, and other indications, based on the research and discoveries from Univ.-Prof. Dr. Wolfram Ruf, the Scientific Director and Alexander von Humboldt Professor at the Center for Thrombosis and Hemostasis (CTH) of the University Medical Center Mainz, and his collaborators. ARCA has potential upfront and milestone obligations to the University Medical Center Mainz that could total approximately €1.6 million and royalty obligations in the low single digit range, if rNAPc2 receives regulatory approval and is commercialized. The term of the Agreement extends to the date of expiration of the last to expire of any of the assigned patents.

The Agreement will be filed as an exhibit to ARCA's June 30, 2021 Quarterly Report on Form 10-Q.

Item 9.01. Financial Statements and Exhibits.



(d) Exhibits.




Exhibit Number          Description

99.1                      Press Release titled "ARCA biopharma Announces rNAPc2
                        COVID-19 Patent Assignment Agreement" dated July 7, 2021  .
104                     Cover Page Interactive Data File. The cover page XBRL tags
                        are embedded within the inline XBRL document (contained in
                        Exhibit 101).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses